Vivos Therapeutics IncVVOS
Price$0.14

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $20.9M+39.1% YoYTTM through 30 Jun 2026
Net Income -$25.5MTTM through 30 Jun 2026
Free Cash Flow -$19MTTM through 30 Jun 2026

Margins

Current
Gross Margin60.4%
EBITDA Margin-99.3%
Operating Margin-114.1%
Net Margin-121.8%

Returns

N/A (negative equity)ROE
-84.2%ROA

Balance Sheet Health

Debt / EquityN/A (negative equity)
Current Ratio0.24x
Net Debt$6.9M
Cash & Equivalents$1.8M

Quality Metrics

Altman Z-Score-10.99
Piotroski F-Score4 / 9
FCF Margin-91.0%
Rule of 40-75.9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $17.4M
Diluted EPS
'22'23'24'25
FY2025: $-2.06

Dividend

No dividend

Capital Allocation

Capex Intensity9.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.